Stock Market news at lse.co.uk - RSS News Feeds

Oxford Biomedica Share News (OXB)



Share News for Oxford Biomedica (OXB)


Share Price: 2.30Bid: 2.20Ask: 2.40Change: 0.00 (0.00%)No Movement on Oxford Biomed.
Spread: 0.20Spread as %: 9.09%Open: 2.375High: 2.39Low: 2.21Yesterday’s Close: 2.30




STOCKS NEWS UK SMALL-Oxford BioMedica rises after IMS

Thu, 14th May 2009 12:18

STOCKS NEWS Reuters

Results diary

Europ
e Real-time Equity News



UK Stocks on the move

UK smallcaps



1040GMT 14May2009-Oxford BioMedica rises after IMS

--------------------------------------------------

Shares in Oxford BioMedica rise 11 percent after the company issues a positive interim management statement.

'Oxford BioMedica provided some encouraging reference points regarding its development pipeline, which position the business on the path to recovery,' say analysts at Panmure Gordon in a note to clients.

However the broker adds that before it changes its 'hold' recommendation, it is waiting for the FDA to clarify the safety of the company's TroVax drug, which failed a Phase III clinical trial in renal cancer last year.

To see the company's statement please click on

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net



1036GMT 14May2009-Luminar up as Numis upgrades to buy

-----------------------------------------------------

Shares in Luminar, Britain's biggest nightclub operator, gain 5.3 percent after the company posts full-year results which Numis Securities says are in line with its expectations.

Luminar says current trading includes an encouraging increase in admissions, as it posts pretax profit of 20.3 million pounds, against 31.5 million pounds the previous year, with an overall same outlet sales decline of 3.8 percent.

'With recent admissions up 3.2 percent, and both admission fees and drinks prices now stabilising, it is possible that like-for-like sales could start to improve,' says Numis in a note, maintaining its forecasts.

The broker lifts its recommendation to 'buy' from 'add' to reflect recent weakness in the shares, and notes that with a 40 percent freehold estate, the 4.4 times EV/EBITDA valuation offers deep value.



1033GMT 14May2009-Prostrakan up on bullish update

-------------------------------------------------

Shares in Prostakan climb 3.3 percent after the Scottish speciality pharmaceutical company delivers 'an exciting mix of better than anticipated revenues' for the first four months of 2009, according to Numis.

Prostrakan reports a 40 percent sales growth for the first four months of 2009 against the same period in 2008.

'Sales of the group's core products surprised positively, with major pan-European products up 50 percent and even the supposedly maturing AdCal D3 up 20 percent,' says Numis in a note.

'With promises kept, everything is on track for ProStrakan to achieve breakeven towards the end of 2009,' the broker adds.

For more double click on

Reuters Messaging rm://david.brett.reuters.com@reuters.net



09:25 GMT 14May2009-Innovation up on share raising plan

--------------------------------------------------------

Innovation Group shares rise as much as 14 percent after the software firm says it plans to raise about 5 million pounds in a share placing to further improve its capital base.

Altium Securities analyst Jonathan Imlah says: 'We have been arguing for some time that Innovation was likely to require strengthening of its balance sheet and therefore welcome today's announcement.'

Imlah says a week ago at the time of its results that Innovation insisted it did not require any further injection of cash. 'What baffles us is the apparent volte face in management's view,' he says.

To see Innovation Group's statement please click on

Reuters messaging rm://purwa.naveen.reuters.com@reuters.net



08:31GMT 14May2009-SQS Software down on profit fall f'cast

----------------------------------------------------------

Shares of SQS Software Quality Systems hit a lifetime low, down 30 percent after the software-testing company forecasts first-half adjusted pretax profit halving.

'We had hoped that offshoring and contractor usage would be able to absorb pricing pressure to a greater extent - although clearly the impact of short-notice cancellations is difficult to manage,' KBC Peel Hunt analyst Alex Jarvis says in a note.

KBC Peel Hunt and Altium Securities downgrade SQS to 'hold' from 'buy'.

For more click on

Reuters messaging rm://shivani.singh.thomsonreuters.com@reuters.net



08:26GMT 14May2009-FTSE small caps down 0.5 pct early

-----------------------------------------------------

The FTSE Small Cap index extends Wednesday's losses, down 0.5 percent in early trade, while the midcaps shed 0.4 percent, and the blue chips are 0.4 percent higher.

Wilmington Group, the British media and services company, falls 14.8 percent, after saying trading between Jan. 1 and March 31 this year has been tougher than expected and warns on its full-year results, with Altium Securities saying it expects to downgrade its earnings forecasts.

Cadogan soars 27.1 percent as investors' confidence is buoyed after the Supreme Court of Ukraine says it will hear the oil and gas explorer's appeal against an earlier ruling on the Pirkovske licence, and it appoints Ian Baron as its chief executive, who will undertake a full strategic and operational review of the business.

Reuters Messaging rm://david.brett.reuters.com@reuters.net



08:05GMT 14May2009-Armour down as H1 profit falls

-------------------------------------------------

Shares in Armour Group fall 10.2 percent after the supplier of in-car and home entertainment products reports a 70 percent fall in pretax profit and says it does not expect conditions in its markets to improve significantly over the coming months.

'We reduce our 2009 pretax profit forecast to 1 million pounds from 1.5 million pounds, with earnings per share reducing to 1.1 pence from 1.9 pence,' says FinnCap analyst David Buxton, adding that he expected the company to see the benefits as its new product and customer development programmes bear fruit.

To see Armour's statement, please click on

Reuters messaging rm://rhysl.jones.reuters.com@reuters.net



07:19GMT 14May2009-Wilmington down on FY warning

------------------------------------------------

Shares in Wilmington Group, the British media and services company, fall 14.8 percent, after saying trading between Jan. 1 and March 31 this year has been tougher than expected and warns on its full-year results.

Altium Securities says in a note: 'We expect to reduce our bottom of the range PBT estimate by around 10 percent (to around 13 million pounds from 14.4 million pounds) and to reduce our target price by a similar quantum.'

Wilmington's pretax profit on continuing businesses fell 39 percent to 2 million pounds ($2.9 million) in the six months ended Dec. 31, and it says a slowdown in its legal training business would likely hit its full-year results.

Keywords: MARKETS STOCKSNEWS UK SMALL



COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.


Related Shares: Oxford Biomedica (OXB) 





STOCKS NEWS EUROPE-Oxford BioMedica up on Novartis deal

Shares in Oxford BioMedica rise 15 percent after the gene-based biopharmaceutical specialist signs a deal to make clinical grade material for Novartis
[1 May '13]

STOCKS NEWS EUROPE-UK small caps edge down 0.1 pct early on

The FTSE Small Cap index sheds 0.1 percent in early deals, underperforming its larger peers with the FTSE 100 up 0.4 percent and the FTSE 250 rising 0
[1 May '13]

BRIEF-Oxford Biomedica says ImaginAb exercises option for licence

LONDON, Nov 29 (Reuters) - Oxford BioMedica PLC: * Imaginab acquires exclusive worldwide licence for 5t4-based imaging diagnostic
[29 Nov '12]

UPDATE 1-Oxford Bio abandons prostate cancer vaccine study

LONDON, Oct 10 (Reuters) - Britain's Oxford BioMedica said on Wednesday it was closing a mid-stage clinical trial of its cancer vaccine TroVax
[10 Oct '12]

BRIEF-Oxford Bio to close prostate cancer study in U.S.

LONDON, Oct 10 (Reuters) - Oxford BioMedica PLC: * To close phase II study in US to assess Trovax in patients with prostate cancer
[10 Oct '12]

BRIEF-Oxford Biomedica to place 11 mln stg

LONDON, June 29 (Reuters) - Oxford BioMedica PLC: * Proposed firm placing of £11 million and open offer of up to £5 million ((London
[29 Jun '12]

BRIEF-Oxford Biomedica's manufacturing facility approved

LONDON, June 8 (Reuters) - Oxford BioMedica PLC: * Approval from the UK mhra for manufacturing facility in cowley, Oxford ((London Eq
[8 Jun '12]

BRIEF-Oxford Biomedica presents ocular clinical data

LONDON, May 8 (Reuters) - Oxford BioMedica PLC: * Presentation of ocular clinical data at arvo * Early retinostat data indicate susta
[8 May '12]



Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.